Universal Biosensors, Inc.
Universal Biosensors, Inc. (UBI.AX) Stock Competitors & Peer Comparison
See (UBI.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| UBI.AX | A$0.01 | +0.00% | 4.2M | -0.23 | -A$0.06 | N/A |
| RMD.AX | A$29.01 | -1.99% | 42.6B | 20.26 | A$1.45 | +1.15% |
| COH.AX | A$97.04 | +0.15% | 6.4B | 18.51 | A$5.27 | +4.41% |
| 4DX.AX | A$3.46 | +5.49% | 2.1B | -9.05 | -A$0.40 | N/A |
| PNV.AX | A$1.27 | +11.89% | 784.1M | 113.50 | A$0.01 | N/A |
| AVR.AX | A$13.37 | +6.62% | 474.9M | -4.12 | -A$3.13 | N/A |
| IMR.AX | A$1.78 | -2.20% | 452.9M | -16.50 | -A$0.11 | N/A |
| EBR.AX | A$0.46 | -11.54% | 220.8M | -1.58 | -A$0.31 | N/A |
| ARX.AX | A$0.62 | +3.33% | 216.2M | -62.50 | -A$0.01 | N/A |
| AVH.AX | A$1.27 | +7.17% | 155.3M | -2.84 | -A$0.44 | N/A |
Stock Comparison
UBI.AX vs RMD.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, RMD.AX has a market cap of 42.6B. Regarding current trading prices, UBI.AX is priced at A$0.01, while RMD.AX trades at A$29.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas RMD.AX's P/E ratio is 20.26. In terms of profitability, UBI.AX's ROE is -1.11%, compared to RMD.AX's ROE of +0.24%. Regarding short-term risk, UBI.AX is more volatile compared to RMD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check RMD.AX's competition here
UBI.AX vs COH.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, COH.AX has a market cap of 6.4B. Regarding current trading prices, UBI.AX is priced at A$0.01, while COH.AX trades at A$97.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas COH.AX's P/E ratio is 18.51. In terms of profitability, UBI.AX's ROE is -1.11%, compared to COH.AX's ROE of +0.18%. Regarding short-term risk, UBI.AX is more volatile compared to COH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check COH.AX's competition here
UBI.AX vs 4DX.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, 4DX.AX has a market cap of 2.1B. Regarding current trading prices, UBI.AX is priced at A$0.01, while 4DX.AX trades at A$3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas 4DX.AX's P/E ratio is -9.05. In terms of profitability, UBI.AX's ROE is -1.11%, compared to 4DX.AX's ROE of -8.91%. Regarding short-term risk, UBI.AX is less volatile compared to 4DX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for UBI.AX.Check 4DX.AX's competition here
UBI.AX vs PNV.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, PNV.AX has a market cap of 784.1M. Regarding current trading prices, UBI.AX is priced at A$0.01, while PNV.AX trades at A$1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas PNV.AX's P/E ratio is 113.50. In terms of profitability, UBI.AX's ROE is -1.11%, compared to PNV.AX's ROE of +0.12%. Regarding short-term risk, UBI.AX is less volatile compared to PNV.AX. This indicates potentially lower risk in terms of short-term price fluctuations for UBI.AX.Check PNV.AX's competition here
UBI.AX vs AVR.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, AVR.AX has a market cap of 474.9M. Regarding current trading prices, UBI.AX is priced at A$0.01, while AVR.AX trades at A$13.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas AVR.AX's P/E ratio is -4.12. In terms of profitability, UBI.AX's ROE is -1.11%, compared to AVR.AX's ROE of -7.74%. Regarding short-term risk, UBI.AX is more volatile compared to AVR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check AVR.AX's competition here
UBI.AX vs IMR.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, IMR.AX has a market cap of 452.9M. Regarding current trading prices, UBI.AX is priced at A$0.01, while IMR.AX trades at A$1.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas IMR.AX's P/E ratio is -16.50. In terms of profitability, UBI.AX's ROE is -1.11%, compared to IMR.AX's ROE of -1.10%. Regarding short-term risk, UBI.AX is more volatile compared to IMR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check IMR.AX's competition here
UBI.AX vs EBR.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, EBR.AX has a market cap of 220.8M. Regarding current trading prices, UBI.AX is priced at A$0.01, while EBR.AX trades at A$0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas EBR.AX's P/E ratio is -1.58. In terms of profitability, UBI.AX's ROE is -1.11%, compared to EBR.AX's ROE of -1.79%. Regarding short-term risk, UBI.AX is more volatile compared to EBR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check EBR.AX's competition here
UBI.AX vs ARX.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, ARX.AX has a market cap of 216.2M. Regarding current trading prices, UBI.AX is priced at A$0.01, while ARX.AX trades at A$0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas ARX.AX's P/E ratio is -62.50. In terms of profitability, UBI.AX's ROE is -1.11%, compared to ARX.AX's ROE of -0.02%. Regarding short-term risk, UBI.AX is more volatile compared to ARX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check ARX.AX's competition here
UBI.AX vs AVH.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, AVH.AX has a market cap of 155.3M. Regarding current trading prices, UBI.AX is priced at A$0.01, while AVH.AX trades at A$1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas AVH.AX's P/E ratio is -2.84. In terms of profitability, UBI.AX's ROE is -1.11%, compared to AVH.AX's ROE of +3.05%. Regarding short-term risk, UBI.AX is more volatile compared to AVH.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check AVH.AX's competition here
UBI.AX vs EMV.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, EMV.AX has a market cap of 155.2M. Regarding current trading prices, UBI.AX is priced at A$0.01, while EMV.AX trades at A$1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas EMV.AX's P/E ratio is -13.92. In terms of profitability, UBI.AX's ROE is -1.11%, compared to EMV.AX's ROE of -0.70%. Regarding short-term risk, UBI.AX is more volatile compared to EMV.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check EMV.AX's competition here
UBI.AX vs SOM.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, SOM.AX has a market cap of 120.5M. Regarding current trading prices, UBI.AX is priced at A$0.01, while SOM.AX trades at A$0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas SOM.AX's P/E ratio is -55.00. In terms of profitability, UBI.AX's ROE is -1.11%, compared to SOM.AX's ROE of -0.05%. Regarding short-term risk, UBI.AX is more volatile compared to SOM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check SOM.AX's competition here
UBI.AX vs CYC.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, CYC.AX has a market cap of 92M. Regarding current trading prices, UBI.AX is priced at A$0.01, while CYC.AX trades at A$0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas CYC.AX's P/E ratio is -4.56. In terms of profitability, UBI.AX's ROE is -1.11%, compared to CYC.AX's ROE of -0.54%. Regarding short-term risk, UBI.AX is more volatile compared to CYC.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check CYC.AX's competition here
UBI.AX vs CMP.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, CMP.AX has a market cap of 54.9M. Regarding current trading prices, UBI.AX is priced at A$0.01, while CMP.AX trades at A$0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas CMP.AX's P/E ratio is -27.50. In terms of profitability, UBI.AX's ROE is -1.11%, compared to CMP.AX's ROE of +0.00%. Regarding short-term risk, UBI.AX is more volatile compared to CMP.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check CMP.AX's competition here
UBI.AX vs RSH.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, RSH.AX has a market cap of 52M. Regarding current trading prices, UBI.AX is priced at A$0.01, while RSH.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas RSH.AX's P/E ratio is -3.30. In terms of profitability, UBI.AX's ROE is -1.11%, compared to RSH.AX's ROE of -4.12%. Regarding short-term risk, UBI.AX is less volatile compared to RSH.AX. This indicates potentially lower risk in terms of short-term price fluctuations for UBI.AX.Check RSH.AX's competition here
UBI.AX vs CSX.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, CSX.AX has a market cap of 32.9M. Regarding current trading prices, UBI.AX is priced at A$0.01, while CSX.AX trades at A$0.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas CSX.AX's P/E ratio is 20.00. In terms of profitability, UBI.AX's ROE is -1.11%, compared to CSX.AX's ROE of +0.09%. Regarding short-term risk, UBI.AX is more volatile compared to CSX.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check CSX.AX's competition here
UBI.AX vs MX1.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, MX1.AX has a market cap of 32.8M. Regarding current trading prices, UBI.AX is priced at A$0.01, while MX1.AX trades at A$0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas MX1.AX's P/E ratio is -2.25. In terms of profitability, UBI.AX's ROE is -1.11%, compared to MX1.AX's ROE of -1.80%. Regarding short-term risk, UBI.AX is more volatile compared to MX1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check MX1.AX's competition here
UBI.AX vs EYE.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, EYE.AX has a market cap of 32.8M. Regarding current trading prices, UBI.AX is priced at A$0.01, while EYE.AX trades at A$0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas EYE.AX's P/E ratio is -5.75. In terms of profitability, UBI.AX's ROE is -1.11%, compared to EYE.AX's ROE of -0.40%. Regarding short-term risk, UBI.AX is more volatile compared to EYE.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check EYE.AX's competition here
UBI.AX vs HMD.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, HMD.AX has a market cap of 31.7M. Regarding current trading prices, UBI.AX is priced at A$0.01, while HMD.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas HMD.AX's P/E ratio is -4.00. In terms of profitability, UBI.AX's ROE is -1.11%, compared to HMD.AX's ROE of -4.18%. Regarding short-term risk, UBI.AX is more volatile compared to HMD.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check HMD.AX's competition here
UBI.AX vs LBT.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, LBT.AX has a market cap of 29.9M. Regarding current trading prices, UBI.AX is priced at A$0.01, while LBT.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas LBT.AX's P/E ratio is -0.42. In terms of profitability, UBI.AX's ROE is -1.11%, compared to LBT.AX's ROE of -3.23%. Regarding short-term risk, UBI.AX is more volatile compared to LBT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check LBT.AX's competition here
UBI.AX vs AT1.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, AT1.AX has a market cap of 19.8M. Regarding current trading prices, UBI.AX is priced at A$0.01, while AT1.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas AT1.AX's P/E ratio is -2.20. In terms of profitability, UBI.AX's ROE is -1.11%, compared to AT1.AX's ROE of -0.58%. Regarding short-term risk, UBI.AX is more volatile compared to AT1.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check AT1.AX's competition here
UBI.AX vs CDX.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, CDX.AX has a market cap of 19.8M. Regarding current trading prices, UBI.AX is priced at A$0.01, while CDX.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas CDX.AX's P/E ratio is -0.90. In terms of profitability, UBI.AX's ROE is -1.11%, compared to CDX.AX's ROE of -2.17%. Regarding short-term risk, UBI.AX is less volatile compared to CDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for UBI.AX.Check CDX.AX's competition here
UBI.AX vs CBL.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, CBL.AX has a market cap of 17.9M. Regarding current trading prices, UBI.AX is priced at A$0.01, while CBL.AX trades at A$0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas CBL.AX's P/E ratio is -2.80. In terms of profitability, UBI.AX's ROE is -1.11%, compared to CBL.AX's ROE of -0.98%. Regarding short-term risk, UBI.AX is more volatile compared to CBL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check CBL.AX's competition here
UBI.AX vs IPD.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, IPD.AX has a market cap of 14.3M. Regarding current trading prices, UBI.AX is priced at A$0.01, while IPD.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas IPD.AX's P/E ratio is -0.70. In terms of profitability, UBI.AX's ROE is -1.11%, compared to IPD.AX's ROE of -1.65%. Regarding short-term risk, UBI.AX is less volatile compared to IPD.AX. This indicates potentially lower risk in terms of short-term price fluctuations for UBI.AX.Check IPD.AX's competition here
UBI.AX vs NTI.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, NTI.AX has a market cap of 12.1M. Regarding current trading prices, UBI.AX is priced at A$0.01, while NTI.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas NTI.AX's P/E ratio is -1.20. In terms of profitability, UBI.AX's ROE is -1.11%, compared to NTI.AX's ROE of -0.87%. Regarding short-term risk, UBI.AX is less volatile compared to NTI.AX. This indicates potentially lower risk in terms of short-term price fluctuations for UBI.AX.Check NTI.AX's competition here
UBI.AX vs RNO.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, RNO.AX has a market cap of 11.5M. Regarding current trading prices, UBI.AX is priced at A$0.01, while RNO.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas RNO.AX's P/E ratio is -1.00. In terms of profitability, UBI.AX's ROE is -1.11%, compared to RNO.AX's ROE of +15.91%. Regarding short-term risk, UBI.AX is more volatile compared to RNO.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check RNO.AX's competition here
UBI.AX vs TRU.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, TRU.AX has a market cap of 9.7M. Regarding current trading prices, UBI.AX is priced at A$0.01, while TRU.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas TRU.AX's P/E ratio is -1.30. In terms of profitability, UBI.AX's ROE is -1.11%, compared to TRU.AX's ROE of -1.13%. Regarding short-term risk, UBI.AX is less volatile compared to TRU.AX. This indicates potentially lower risk in terms of short-term price fluctuations for UBI.AX.Check TRU.AX's competition here
UBI.AX vs OSL.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, OSL.AX has a market cap of 9.6M. Regarding current trading prices, UBI.AX is priced at A$0.01, while OSL.AX trades at A$0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas OSL.AX's P/E ratio is -0.54. In terms of profitability, UBI.AX's ROE is -1.11%, compared to OSL.AX's ROE of -3.72%. Regarding short-term risk, UBI.AX is more volatile compared to OSL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check OSL.AX's competition here
UBI.AX vs IRX.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, IRX.AX has a market cap of 6.9M. Regarding current trading prices, UBI.AX is priced at A$0.01, while IRX.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas IRX.AX's P/E ratio is -2.80. In terms of profitability, UBI.AX's ROE is -1.11%, compared to IRX.AX's ROE of +2.96%. Regarding short-term risk, UBI.AX is less volatile compared to IRX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for UBI.AX.Check IRX.AX's competition here
UBI.AX vs OVN.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, OVN.AX has a market cap of 4.8M. Regarding current trading prices, UBI.AX is priced at A$0.01, while OVN.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas OVN.AX's P/E ratio is -0.40. In terms of profitability, UBI.AX's ROE is -1.11%, compared to OVN.AX's ROE of -0.80%. Regarding short-term risk, UBI.AX is more volatile compared to OVN.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check OVN.AX's competition here
UBI.AX vs ALT.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, ALT.AX has a market cap of 4.6M. Regarding current trading prices, UBI.AX is priced at A$0.01, while ALT.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas ALT.AX's P/E ratio is N/A. In terms of profitability, UBI.AX's ROE is -1.11%, compared to ALT.AX's ROE of -2.31%. Regarding short-term risk, UBI.AX is more volatile compared to ALT.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check ALT.AX's competition here
UBI.AX vs ADR.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, ADR.AX has a market cap of 3.9M. Regarding current trading prices, UBI.AX is priced at A$0.01, while ADR.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas ADR.AX's P/E ratio is -0.20. In terms of profitability, UBI.AX's ROE is -1.11%, compared to ADR.AX's ROE of +4.60%. Regarding short-term risk, UBI.AX is more volatile compared to ADR.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check ADR.AX's competition here
UBI.AX vs VTI.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, VTI.AX has a market cap of 3.7M. Regarding current trading prices, UBI.AX is priced at A$0.01, while VTI.AX trades at A$0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas VTI.AX's P/E ratio is -0.55. In terms of profitability, UBI.AX's ROE is -1.11%, compared to VTI.AX's ROE of -0.57%. Regarding short-term risk, UBI.AX is more volatile compared to VTI.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check VTI.AX's competition here
UBI.AX vs AMT.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, AMT.AX has a market cap of 3.5M. Regarding current trading prices, UBI.AX is priced at A$0.01, while AMT.AX trades at A$0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas AMT.AX's P/E ratio is -1.45. In terms of profitability, UBI.AX's ROE is -1.11%, compared to AMT.AX's ROE of -11.52%. Regarding short-term risk, UBI.AX is less volatile compared to AMT.AX. This indicates potentially lower risk in terms of short-term price fluctuations for UBI.AX.Check AMT.AX's competition here
UBI.AX vs UCM.AX Comparison May 2026
UBI.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, UBI.AX stands at 4.2M. In comparison, UCM.AX has a market cap of 3.1M. Regarding current trading prices, UBI.AX is priced at A$0.01, while UCM.AX trades at A$0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
UBI.AX currently has a P/E ratio of -0.23, whereas UCM.AX's P/E ratio is -0.60. In terms of profitability, UBI.AX's ROE is -1.11%, compared to UCM.AX's ROE of -3.58%. Regarding short-term risk, UBI.AX is more volatile compared to UCM.AX. This indicates potentially higher risk in terms of short-term price fluctuations for UBI.AX.Check UCM.AX's competition here